An efficient plasmid-based system for the recovery of recombinant vesicular stomatitis virus encoding foreign glycoproteins

María-Carmen Marqués,Iván Andreu-Moreno,Rafael Sanjuán,Santiago F. Elena,Ron Geller

DOI: https://doi.org/10.1038/s41598-024-65384-8

IF: 4.6

2024-06-27

Scientific Reports

Abstract:Viral glycoproteins mediate entry into host cells, thereby dictating host range and pathogenesis. In addition, they constitute the principal target of neutralizing antibody responses, making them important antigens in vaccine development. Recombinant vesicular stomatitis virus (VSV) encoding foreign glycoproteins can provide a convenient and safe surrogate system to interrogate the function, evolution, and antigenicity of viral glycoproteins from viruses that are difficult to manipulate or those requiring high biosafety level containment. However, the production of recombinant VSV can be technically challenging. In this work, we present an efficient and robust plasmid-based system for the production of recombinant VSV encoding foreign glycoproteins. We validate the system using glycoproteins from different viral families, including arenaviruses, coronaviruses, and hantaviruses, as well as highlight their utility for studying the effects of mutations on viral fitness. Overall, the methods described herein can facilitate the study of both native and recombinant VSV encoding foreign glycoproteins and can serve as the basis for the production of VSV-based vaccines.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop an efficient, safe and robust plasmid system for the production of recombinant vesicular stomatitis virus (VSV) encoding exogenous glycoproteins. Specifically, the goals of the paper are as follows:

1. **Improve the production efficiency of recombinant VSV**: Traditional methods for producing recombinant VSV rely on the use of vaccinia virus with T7 polymerase (VACV - T7), which not only increases the biosafety risk but may also lead to mutual interference between VACV and recombinant VSV, thereby affecting the recovery rate of recombinant VSV. Therefore, researchers hope to develop a method that does not depend on VACV - T7 to improve the production efficiency of recombinant VSV.

2. **Be compatible with glycoproteins of multiple virus families**: The glycoproteins of many viruses are of important biological significance in terms of function, but these viruses may be difficult to manipulate or require high - biosafety - level laboratory conditions. By developing a system that can efficiently express glycoproteins of different virus families, it is more convenient to study the functions, evolution and antigenicity of these glycoproteins.

3. **Evaluate the impact of glycoproteins on virus adaptability**: Recombinant VSV can be used to study the impact of different glycoproteins on virus adaptability. Through competition experiments and virus transmission experiments, researchers can evaluate the virus adaptability of different glycoprotein variants, which is of great significance for understanding virus evolution and developing vaccines.

4. **Promote vaccine and therapeutic research**: The ability of recombinant VSV to encode exogenous glycoproteins makes it an important tool for developing new vaccines and treatment methods. By optimizing the production method of recombinant VSV, the progress of these research can be accelerated.

In summary, the main goal of this paper is to develop an efficient plasmid system for the production of recombinant VSV encoding exogenous glycoproteins, thereby promoting the functional research of viral glycoproteins, the evaluation of virus adaptability, and the development of vaccine and therapeutic research.